A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Interstitial cystitis
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 11 Sep 2017 Planned End Date changed from 1 May 2018 to 11 Nov 2017.
    • 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top